Entrada Therapeutics Inc (TRDA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Entrada Therapeutics Inc   (NASDAQ: TRDA)


Entrada Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Entrada Therapeutics Inc's ROI in the second quarter of 2026?
Entrada Therapeutics Inc achieved a return on average invested assets (ROI) of 10.15 % in its second quarter of 2026, which is below Entrada Therapeutics Inc's average return on investment, which stands at 10.29%.

ROI has improved compared to 9.07% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 83 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 549 to 931.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -28.49 % -23.15 % -9.15 % 8.93 % 27.67 %
Y / Y Net Income Change TTM - -30.57 % - - -
Investment (TTM) in Millions 278 316 353 389 429
Return On Investment (TTM) 10.15 % 9.07 % -0.23 % -15.1 % -13.79 %
TRDA's Overall Ranking # 931 # 549 # 1928 # 2848 # 0
Seq. Investment Change TTM -10.19 % -9.26 % -7.55 % -5.09 % -3.47 %
Seq. Net Income Change TTM 0.42 % - - - -
Net Income (TTM) in Millions 34 34 -1 -67 -64

TRDA Company Profile >> Back to TRDA Roi Comparisons >> See Annual TRDA Return On Investment



Return On Investment TRDA's Ranking
Within: No.
Industry # 30
Sector # 84
Overall # 931

Return On Investment Statistics
High Average Low
154.28 %
10.29 %
-46.09 %
(Dec 31 2021)   (Sep 30 2021)







Financial Statements
Entrada Therapeutics Inc's II. Quarter Investments $ 278 Millions TRDA's Balance sheet
Entrada Therapeutics Inc's II. Quarter Income $ 0 Millions Quarterly TRDA's Income Statement
TRDA's Income by Division See TRDA's Income by Division


TRDA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 353 487 310 230 299
Y / Y Investment Growth -27.51 % 56.84 % 34.91 % -23.08 % -
Net Income in Millions -1 132 5 -95 -51
Y / Y Net Income Growth - 2359.71 % - - -
Annual Return On Investment -0.26 % 27.14 % 1.73 % -41.12 % -17.1 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
TRDA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for TRDA's Competitors
Subscribers only: Roi for Entrada Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for TRDA's Customers

Other Ratios
TRDA's Roa TRDA's Inventory Turnover Ratio TRDA's Growth Rates TRDA's Dividend Statistics
TRDA's Profitability Ratios TRDA's Asset Turnover Ratio TRDA's Dividend Growth
TRDA's Roe TRDA's Valuation Ratios TRDA's Financial Strength Ratios TRDA's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %
Neurocrine Biosciences Inc   17.51 %
Intuitive Surgical Inc   17.11 %
Theravance Biopharma inc   17.10 %
Standard Biotools Inc   16.38 %
Inspire Medical Systems inc   16.34 %
Aveanna Healthcare Holdings Inc   16.32 %
Harmony Biosciences Holdings inc   15.85 %
Entera Bio Ltd   15.84 %

Date modified: 2026-09-08T22:40:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.